CO7190239A2 - Dialisato a base de polímero - Google Patents

Dialisato a base de polímero

Info

Publication number
CO7190239A2
CO7190239A2 CO14250262A CO14250262A CO7190239A2 CO 7190239 A2 CO7190239 A2 CO 7190239A2 CO 14250262 A CO14250262 A CO 14250262A CO 14250262 A CO14250262 A CO 14250262A CO 7190239 A2 CO7190239 A2 CO 7190239A2
Authority
CO
Colombia
Prior art keywords
polymer based
dialysate
based dialysate
polyglycerol
kda
Prior art date
Application number
CO14250262A
Other languages
English (en)
Inventor
Jayachandran Kizhakkedathu
Caigan Du
Roza Gerald Da
Asher Mendelson
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of CO7190239A2 publication Critical patent/CO7190239A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/22—Cyclic ethers having at least one atom other than carbon and hydrogen outside the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0014—Special media to be introduced, removed or treated removed from the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0496—Urine
    • A61M2202/0498—Urea
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2340/00—Filter material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

Las incorporaciones descritas en el presente proporcionan un dialisato que comprende un poliglicerol. El poliglicerol puede tener un peso molecular entre alrededor de 0.15 kDa a alrededor de 60 kDa. También se proporciona en el presente el uso del dialisato como un agente de difusión y como un agente osmótico.
CO14250262A 2012-04-24 2014-11-12 Dialisato a base de polímero CO7190239A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261637716P 2012-04-24 2012-04-24

Publications (1)

Publication Number Publication Date
CO7190239A2 true CO7190239A2 (es) 2015-02-19

Family

ID=49482059

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14250262A CO7190239A2 (es) 2012-04-24 2014-11-12 Dialisato a base de polímero

Country Status (15)

Country Link
US (1) US9919004B2 (es)
EP (1) EP2841078A4 (es)
JP (1) JP6240665B2 (es)
KR (1) KR20150013161A (es)
CN (1) CN104640550A (es)
AU (1) AU2013252433B2 (es)
BR (1) BR112014026616A2 (es)
CA (1) CA2871277A1 (es)
CL (1) CL2014002891A1 (es)
CO (1) CO7190239A2 (es)
HK (1) HK1203388A1 (es)
MX (1) MX2014012942A (es)
MY (1) MY170307A (es)
PE (1) PE20150288A1 (es)
WO (1) WO2013159188A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9346029B2 (en) 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
CA2999629C (en) 2010-03-01 2020-12-15 The University Of British Columbia Derivatized hyperbranched polyglycerols
ES2800605T3 (es) 2013-11-21 2021-01-04 Jayachandran Kizhakkedathu Solución de preservación del trasplante basada en polímeros
US10202507B2 (en) 2014-05-29 2019-02-12 The University Of British Columbia Antithrombotic compounds, methods and uses thereof
EP3120842A1 (en) * 2015-07-20 2017-01-25 Opterion Health AG Peritoneal therapeutic fluid
JP6721880B2 (ja) * 2016-03-25 2020-07-15 国立大学法人神戸大学 正浸透膜を使用して膜分離する方法
US10874790B2 (en) 2016-08-10 2020-12-29 Medtronic, Inc. Peritoneal dialysis intracycle osmotic agent adjustment
GR1009311B (el) * 2017-01-26 2018-06-19 Βερμα Ντραγκς - Verma Drugs Abee Οξινο κιτρικο διαλυμα αιμοκαθαρσης με l-καρνιτινη
EP3381484A1 (en) * 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
WO2019210414A1 (en) * 2018-05-02 2019-11-07 Arc Medical Devices Inc. Fucan-based compounds and complexes
US11806457B2 (en) 2018-11-16 2023-11-07 Mozarc Medical Us Llc Peritoneal dialysis adequacy meaurements
US11806456B2 (en) 2018-12-10 2023-11-07 Mozarc Medical Us Llc Precision peritoneal dialysis therapy based on dialysis adequacy measurements
US11965763B2 (en) 2021-11-12 2024-04-23 Mozarc Medical Us Llc Determining fluid flow across rotary pump

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461210A (en) 1967-07-20 1969-08-12 Unimed Inc Reduction of intraocular pressure
JPS61247466A (ja) * 1985-04-25 1986-11-04 テルモ株式会社 腹膜透析用透析液
ATE311203T1 (de) 1999-10-15 2005-12-15 Dow Global Technologies Inc Dialyselösung die polyglycol als osmotischen mittels enthält
US20030202958A1 (en) * 1999-10-15 2003-10-30 Strickland Alan D. Dialysis solution including polyglycol osmotic agent
US6949335B2 (en) 1999-11-30 2005-09-27 21St Century Medicine, Inc. Polyglycerol and lactose compositions for the protection of living systems from states of reduced metabolism
US9346029B2 (en) * 2005-06-06 2016-05-24 The University Of British Columbia Polymer-based serum albumin substitute
DE102006036326A1 (de) 2006-08-03 2008-02-07 Charité - Universitätsmedizin Berlin Dendritische Polyglycerolsulfate und -sulfonate und deren Verwendung bei entzündlichen Erkrankungen
WO2008074154A1 (en) 2006-12-18 2008-06-26 The University Of British Columbia Polymers comprising zwitterionic endgroups
CA2742345A1 (en) 2007-11-02 2009-05-07 The University Of British Columbia Hyperbranched polyglycerol for improving heart function
CA2999629C (en) 2010-03-01 2020-12-15 The University Of British Columbia Derivatized hyperbranched polyglycerols
WO2012162789A1 (en) 2011-06-01 2012-12-06 University Of British Columbia Polymers for reversing heparin-based anticoagulation

Also Published As

Publication number Publication date
MX2014012942A (es) 2015-02-10
AU2013252433B2 (en) 2017-12-14
MY170307A (en) 2019-07-17
WO2013159188A1 (en) 2013-10-31
EP2841078A4 (en) 2015-11-04
CA2871277A1 (en) 2013-10-31
PE20150288A1 (es) 2015-02-22
US9919004B2 (en) 2018-03-20
AU2013252433A1 (en) 2014-11-20
BR112014026616A2 (pt) 2017-06-27
US20150141512A1 (en) 2015-05-21
CL2014002891A1 (es) 2015-05-04
JP6240665B2 (ja) 2017-11-29
HK1203388A1 (en) 2015-10-30
KR20150013161A (ko) 2015-02-04
JP2015515481A (ja) 2015-05-28
EP2841078A1 (en) 2015-03-04
CN104640550A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
CO7190239A2 (es) Dialisato a base de polímero
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
GT201500063A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas
BR112015027321A2 (pt) composições e métodos
ECSP15026557A (es) Compuestos y sus métodos de empleo
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
ECSP10010206A (es) Inhibidores de la replicación del virus de la imunodeficiencia humana
UY34538A (es) Heteroarilos y usos de los mismos
CR20150250A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
UY34419A (es) Profármaco de adrenomedulina basado en polietilenglicol y el uso del mismo
CR20150440A (es) Nuevos derivados de piridina
CR20150211A (es) Compuestos diméricos
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
UY34773A (es) Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
DOP2016000021A (es) Imidazotiazol sulfonamidas como nematicidas
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
CR20120166A (es) Composiciones y productos antimicrobianos
AR095937A1 (es) Potenciador de la solubilidad en agua a base de glucógeno
BR112014012325A2 (pt) fibra de poliolefina
CR20150641U (es) Composiciones farmacéuticas
UY4229Q (es) Mesa de juego con taburete para niños